Market Events and Forecast | Nephrology | US/EU5 | 2021
In 2019, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled almost $3.98 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, biosimilars of Aranesp / Nesp (darbepoetin alfa) and Mircera (methoxy polyethylene glycol-epoetin beta) are expected to enter the major markets, alongside currently available epoetin alfa biosimilars, further increasing the need for companies to set competitive pricing to either gain or maintain ESA patient shares. We present our ESA forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.
Related Market Assessment Reports
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Heart Failure (US)
Chronic heart failure (CHF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. The CHF therapy market…
Report
Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications…
Report
Migraine – Current Treatment – Treatment Algorithms: Claims Data Analysis – Migraine Prophylaxis (US)
Migraine is a common neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
